ArticleJournal of cardiothoracic surgery2025
Comparison of efficacy and safety in two versus three cycles of neoadjuvant immunotherapy plus chemotherapy for esophageal squamous cell carcinoma.
Article in Journal of cardiothoracic surgery, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Reassessing the role of combined organ resection in cT4b esophageal cancer: feasibility, outcomes, and future directions.Journal of thoracic disease · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
Abstract
purposeThis research aimed to compare the efficacy and safety in two versus three cycles of neoadjuvant immunotherapy plus chemotherapy for esophageal squamous cell carcinoma. MATERIALS AND
methodsPatients with esophageal squamous cell carcinoma receiving neoadjuvant immunotherapy plus albumin-bound paclitaxel and platinum-based chemotherapy followed by esophagectomy from December 2020 to May 2024 were retrospectively analyzed. The therapeutic efficacy, adverse reactions, and postoperative complications between the two- and three-cycle groups were analyzed using chi-square test and independent sample t-test. The overall survival (OS) and progression-free survival (PFS) were estimated by the Kaplan-Meier method with log-rank test.
resultsA total of 138 esophageal squamous cell carcinoma patients receiving neoadjuvant immunotherapy plus chemotherapy were enrolled. The R0 resection rates were 94.5% and 95.7% in the two- and three-cycle groups, respectively (P = 0.554). The pathological complete response and major pathological response rates in the two-cycle group were 19.8% and 40.7%, while they were 21.3% and 38.3% in the three-cycle group, respectively, with no significant differences (P = 0.836 and P = 0.788). More anemia cases appeared in the three-cycle group (27.7% vs. 13.2%, P = 0.036). There were no significant differences between the two- and three-cycle groups in terms of anastomotic fistula, pulmonary infection, chylothorax, and multiple organ dysfunction syndrome. Additionally, The 3-year OS rates of patients in the two- and three-cycle groups were 80.1% and 74.5%, respectively, without significant difference (P = 0.421). The 3-year PFS rates in the two- and three-cycle groups were 62.5% and 65.8%, respectively, without significant difference either (P = 0.966).
conclusionsTwo-cycle neoadjuvant immunotherapy combined with albumin-bound paclitaxel and platinum based chemotherapy can be an effective, safe, and optional neoadjuvant strategy for esophageal squmous cell carcinoma patients.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.